Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada

Knowles, S.R., Phillips, E.J., Dresser, L. and Matukas, L. (2003) Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clinical Infectious Diseases, 37 (8). pp. 1139-1142.

Abstract

Although information on efficacy and adverse drug reactions is lacking, ribavirin has been used empirically for the treatment of severe acute respiratory syndrome (SARS). We report common adverse events in 110 patients with suspected or probable SARS who were treated with ribavirin. Sixty-one percent of the patients had evidence of hemolytic anemia, and hypocalcemia and hypomagnesmia were reported in 58% and 46% of patients, respectively.

Item Type:	Journal Article
Publisher:	University of Chicago Press
Copyright:	© 2003 by the Infectious Diseases Society of America
URI:	http://researchrepository.murdoch.edu.au/id/eprint/16092

Item Control Page

Downloads